Study of a once-monthly injection for stable schizophrenia
Treatments studied
Part of Mental health clinical trials.
This trial tests a long-acting injectable form of cariprazine (AX251 LAI) for people with stable schizophrenia. You would receive one injection and stay at the clinic for 7 days to see how your body handles it and how well you tolerate it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have a diagnosis of schizophrenia (not other conditions like bipolar or schizoaffective disorder).
- Your symptoms are relatively stable (you score 75 or lower on a standard symptom scale).
- You are currently taking one or two antipsychotic medications (other than cariprazine) and have been on them for at least 3 months.
- You have either taken cariprazine before without problems or are willing to try it for a few days.
- You are willing to stay at the study site for about a week after receiving the study injection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a monthly injection of cariprazine (a medication for mental health conditions) in people who could benefit from it. It aims to see if the shot is safe, tolerable, and effective compared to taking pills every day.
This study tests a new extended-release injection for schizophrenia, comparing it to the existing drug Vraylar. It's for people who are currently stable on their antipsychotic medication and have tolerated oral cariprazine before.
This trial tests whether a new version of an extended-release injection is as effective as the original in people with schizophrenia. The study helps ensure patients have access to a reliable treatment option.
This study tests how well a new aripiprazole injection works in your body compared to a standard version. You'll receive injections while your schizophrenia symptoms are stable, and researchers will measure drug levels in your blood to ensure the new version works the same way.
This trial tests an experimental medicine, LTX-001, for people with schizophrenia who are currently having a sudden worsening of symptoms. It aims to see if the drug can help reduce these acute symptoms.
This study uses brain scans (PET and MRI) to see how a specific receptor, called D3, is affected by antipsychotic medications in people with schizophrenia. You may be able to participate if you have not taken antipsychotics for at least 3 weeks and are not using nicotine products.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.